Global Top Players in Intraocular Lens (IOL) Market

Ophthalmology

One of the leading causes of blindness, and a s...

Uveitis is an ocular inflammation of the uveal tract, the middle layer of the eyeball. The uveal layer is responsible for nourishing the eye, and if damaged, leads to progressive and irreversible d...

May 29, 2020

Retinitis pigmentosa
What is driving Retinitis pigmentosa market forward?

DelveInsight estimates an increase in Retinitis Pigmentosa Market Size during the study period 2017–2030, from USD 237.27 million, as reported in 2017 in the 7MM. The increase in the Retinitis pigmentosa market size, as estimated by DelveInsight, is a direct consequence of the expected launch of potential therap...

Find More
Retinitis Pigmentosa
Retinitis Pigmentosa: A complex disease, and the increasing gap between prevalence and diagnosed prevalence

DelveInsight’s Retinitis Pigmentosa Epidemiology forecast analysis revealed that the prevalent population of the disease is expected to increase during the study period 2017-30. Retinitis Pigmentosa Defects and Diagnosis A group of inherited genetic retinal diseases – Retinitis pigmentosa – leads to progressi...

Find More
Wet Age-related macular degeneration treatment market
Promising therapies that might shift Wet Age-related Macular Degeneration Market in the next decade

With no effective cure in Wet Age-related macular degeneration (Wet AMD) treatment market, the need of new therapies that can not only slow down the progression of the vision loss but also kill the cause behind the degeneration of the macula. The present treatment approach requires intravitreal injection of anti-VE...

Find More

More Views & Analysis

Wet Age-Related Macular Degeneration
Wet Age-Related Macular Degeneration: Unravelling the complex disease with comprehensive R&D

Nearly 11 million Americans are living with one or other type of Age-Related Macular degeneration (AMD), estimates BrightFocus foundation. Age-related macular degeneration – one of the leading causes of irreversible blindness in adults over 50 years old – is a consequence of degeneration of macula present in the sm...

Find More

thyroid eye disease
Thyroid awareness month

January month is the Thyroid awareness month, and it is a great way to comprehend the treatment, prevention, and causes of thyroid-related diseases and cancer for the people who are affected.One of them is Thyroid eye disease, which is also known as Graves' Orbitopathy or Ophthalmopathy that is an autoimmune disea...

Find More

Thyroid eye disease
Thyroid eye disease market: New therapies enter the TED market

The newly approved drug teprotumumab can offer hope to adults with thyroid eye disease, a rare and potentially blinding condition. It's the first treatment specifically approved for thyroid eye disease. The drug of Horizon Therapeutics was approved by the U.S. Food and Drug Administration and is set to be marketed ...

Find More

Pharma News
Cumberland’s methotrexate product gets approval in the US; Baker Brothers purchases stake in Kodiak’s KSI-301; Sanofi offloads Seprafilm unit to Baxter

Cumberland Pharmaceuticals has recently received approval from the US FDA for its RediTrex injection for the treatment of rheumatoid arthritis. Cumberland pharmaceuticals pharma company focusing on acquiring and commercializing prescription products has gained access to the injection from Nordic Group two years...

Find More

Geographic atrophy market
Geographic Atrophy Treatment Market: Novel Therapies to Enter the Market

Geographic atrophy (GA) is a severe, progressive, irreversible vision loss in old age people. The loss in the vision is due to the damage in a small portion of the retina at the back of the eye, known as the macula. Since the loss of vision is due to age, it is also referred to as Age-related macular degeneration. ...

Find More

retinal disease pipeline portfolio
Boehringer Ingelheim ties up with Inflammasome Therapeutics

Boehringer Ingelheim and Inflammasome Therapeutics Inc. have announced that they have entered into a definitive a co-development and license agreement to develop therapies for the patients with retinal diseases.The deal is about jointly developing three novel therapies for retinal diseases with the help of Inflamma...

Find More

A rare autosomal recessive disorder, Familial chylomicronemia syndrome (FCS), affects 1 in 1 to 2 mi.....

Find More

Immunity is a major concern in the present times, and consumers have increased their focus on boosti.....

Find More

A chronic pain condition, Complex Regional Pain Syndrome (CRPS) often affects one limb and is believ.....

Find More

Ankylosing spondylitis (AS) is an inflammatory disease that results in a progressive fusion of some .....

Find More

Alzheimer's disease is an irreversible, progressive disorder of the brain that progressively destroy.....

Find More

Immunotherapies, a potentially life-saving therapy, have benefitted several patients suffering from .....

Find More